Development & Preliminary Clinical Validation Blue Light Phototherapy Systems for T-Cell
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Northwestern University
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.
Study Overview
Brief Summary
This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 89 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient's aged 18-89 at time of enrollment
- •Previous diagnosis of psoriasis vulgaris or Grover's disease
Exclusion Criteria
- •All Groups: Subjects who are younger than 18 years of age or older than 90 years of age
- •Patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy
- •Patients prescribed any of the following drugs for issues not related to their psoriasis or Grover's disease
- •topical steroids
- •calcineurin inhibitors
- •methotrexate
- •retinoids
- •biologic agents
- •Unable to schedule phototherapy sessions
- •We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.
Arms & Interventions
Adult treatment arm
Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.
Intervention: Blue light phototherapy (Device)
Outcomes
Primary Outcomes
Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.
Time Frame: Time Frame: 5 weeks
The DLQI is a questionnaire with 10 questions. The maximum score is 30 and minimum is 0. The higher the score, the more quality of life is impaired.
Efficacy of Blue Light Therapy for Patients With Grover's Disease
Time Frame: Time Frame: 5 weeks
Demonstrate preliminary skin efficacy as measured by lesion count
Secondary Outcomes
No secondary outcomes reported
Investigators
Shuai (Steve) Xu
Principal Investigator
Northwestern University